What determines the choice of STN versus GPi as the target?
In the future, the target choice will be made based upon what will give the best result for an individual patient’s symptoms. At this time, data show that both STN and GPi DBS are effective for most symptoms, and it is not clear if one is a better target. For patients who were enrolled in our formal clinical trial of DBS for PD, the choice of STN or GPi is determined by randomization. If not enrolled in the trial, the target choice is made largely by preference of the patient and referring neurologist.
